Morgan Stanley raised the firm’s price target on Fresenius SE (FSNUY) to EUR 41 from EUR 40 and keeps an Overweight rating on the shares.

DaVita’s strong services face risks from debt and economic uncertainties. Find out why DVA stock is a "Hold" with a $130 ...

The healthcare company lifted its full-year guidance after a robust third quarter driven by Kabi and good organic growth at ...

Third Quarter 2024 Results Key Financial Results Revenue: €5.37b (up 3.5% from 3Q ...

Fresenius Se ( (FSNUY) ) has released its Q3 earnings. Here is a breakdown of the information Fresenius Se presented to its investors.

Fresenius SE’s historical prowess in dialysis and injectable therapies has created opportunities to vertically integrate into several medical service and technology businesses by organic and ...

Deutsche Bank raised the firm’s price target on Fresenius SE (FSNUY) to EUR 44 from EUR 42 and keeps a Buy rating on the shares. The views and opinions expressed herein are the views and ...

But if you pick the right individual stocks, you could make more than that. To wit, the Fresenius SE & Co. KGaA (ETR:FRE) share price is 41% higher than it was a year ago, much better than the ...

JPMorgan raised the firm’s price target on Fresenius SE (FSNUY) to EUR 41.90 from EUR 40.10 and keeps an Overweight rating on the shares. The views and opinions expressed herein are the views ...

Narrow-moat Fresenius SE turned in strong third-quarter results helped by rising medical utilization, and management increased its 2024 outlook ranges. To account for recent cash flow generated ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Fresenius SE FRE0.18%increase; green up pointing triangle raised its full-year guidance after a strong third quarter driven by Kabi and good organic growth at Helios. The German healthcare company ...